Cholecystectomy and Acquired Factor VIII Inhibitor Coagulopathy

September 2004
American Surgeon;Sep2004, Vol. 70 Issue 9, p815
Academic Journal
The purpose of this study was to describe the outcome of patients undergoing surgery with recognized and unrecognized factor VIII inhibitor. The setting was a tertiary care center with a community-based general surgery training program. Two patients with acquired factor VIII inhibitor coagulopathy required cholecystectomy. Interventions included intravenous immunoglobulin (IVIG) and factor VIII transfusions. An elderly patient undergoing urgent open cholecystectomy for acute cholecystitis exsanguinated despite postoperative recognition and treatment of factor VIII inhibitor. A second patient with known factor VIII inhibitor underwent laparoscopic cholecystectomy with perioperative transfusions of factor VIII and IVIG. No hemorrhage occurred, but cost to the patient exceeded $50,000. Acquired factor VIII inhibitor coagulopathy is rare and potentially lethal. Preoperative recognition and appropriate hematologic intervention is crucial to achieve a successful outcome.


Related Articles

  • Development of inhibitors with recombinant factor VIII products.  // Reactions Weekly;10/22/2005, Issue 1074, p2 

    Reports on the development of antibodies against factor VIII inhibitors in previously treated patients for all recombinant factor VIII products according to the Committee for Medicinal Products for Human Use of the European Agency (EMEA) for the Evaluation of Medicinal Products in 2005. ...

  • Proteolytic Antibodies against Factor VIII in Hemophilia A. Stollar, B. David // New England Journal of Medicine;2/28/2002, Vol. 346 Issue 9, p702 

    Editorial. Focuses on inhibitory antibodies to factor VIII that arise in patients with hemophilia A who receive replacement therapy with factor VIII protein. How the antibodies complicate the treatment of hemophilia; Mentions an article in this issue by Lacroix-Desmazes and others; Description...

  • Haemophilia A: meeting the needs of individual patients. Khair, Kate; Geraghty, Susan J. // British Journal of Nursing;9/13/2007, Vol. 16 Issue 16, p987 

    The unpredictable nature of bleeding and complications, and the highly variable nature of haemophilia A, necessitate that each patient be dealt with on an individual basis with treatment tailored to specific needs. Safety of treatment is paramount and, due to concerns over viral safety, the use...

  • Factor VIII.  // Reactions Weekly;5/8/2010, Issue 1300, p21 

    The article describes the case of a 7-month-old boy with severe haemophilia A who acquired factor VIII inhibitors while taking a third generation recombinant FVIII product.

  • Plasma exchange and human factor VIII concentrate in managing haemophilia A with factor VIII inhibitors. Wensley, Richard T.; Stevens, Richard F.; Burn, Aileen M.; Delamore, Irvine W. // British Medical Journal;11/22/1980, Vol. 281 Issue 6252, p1388 

    Investigates the effectiveness of plasma exchange and human factor VIII concentrate in treating hemophilia A with factor VIII inhibitors. Medical interventions for the disease; Decrease in the levels of factor VIII inhibitors; Role of factor VIII in neutralizing inhibitor levels.

  • Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Lian, Eric C-Y.; Larcada, Alberto F.; Chiu, Aidan Y-Z; Lian, E C; Larcada, A F; Chiu, A Y // Annals of Internal Medicine;5/15/89, Vol. 110 Issue 10, p774 

    Study Objective: To evaluate the effectiveness of combined cyclophosphamide, vincristine, and prednisone (CVP) therapy after antigenic stimulation with factor VIII in the eradication of factor VIII inhibitor.Design: Factor VIII activity and inhibitor titer were measured...

  • Therapy-resistant haemarthros in a patient with factor VIII inhibitor: successful treatment with recombinant factor VIIa. Lenz, E.; Repas-Humpe, M.; Oldenburg, J.; Kreuz, W.; Schröter, W.; Eber, S. W.; Schröter, W // European Journal of Pediatrics;1999, Vol. 158 Issue 11, p951 

    Discusses the treatment of therapy-resistant haemarthos in a patient with factor VIII inhibitor through the use of recombinant factor VIIa. Administration of activated prothrombin complex; Information on bleeding episodes in haemophilia A patients with high titre inhibitor; Inhibitor titre under...

  • The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A. Lacroix-Desmazes, Sébastien; Bayry, Jagadeesh; Misra, Namita; Horn, Michael P.; Villard, Sylvie; Pashov, Anastas; Stieltjes, Natalie; d'Oiron, Roseline; Saint-Remy, Jean-Marie; Hoebeke, Johan; Kazatchkine, Michel D.; Reinbolt, Joseph; Mohanty, Dipika; Kaveri, Srini V. // New England Journal of Medicine;2/28/2002, Vol. 346 Issue 9, p662 

    Background: Factor VIII inhibitors are IgG alloantibodies that arise during replacement therapy in 25 to 50 percent of patients with severe hemophilia A. The hydrolysis of factor VIII by anti–factor VIII antibodies has been proposed as a mechanism of inactivation of factor VIII. Methods:...

  • Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience. Ellinor I B Peerschke; Donna D Castellone; Marlies Ledford-Kraemer; Elizabeth M Van Cott; Piet Meijer // American Journal of Clinical Pathology;Apr2009, Vol. 131 Issue 4, p552 

    Quantification of inhibitory antibodies against infused factor VIII (FVIII) has an important role in the management of patients with hemophilia A. This article summarizes results from the largest North American FVIII inhibitor proficiency testing challenge conducted to date. Test samples, 4...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics